The objectives of this observational study are to assess the long-term safety and long-term effectiveness of burosumab in patients with TIO who are being treated with burosumab as prescribed by their physician and to monitor the course of the underlying phosphaturic mesenchymal tumor (PMT) overtime in patients with TIO irrespective of their treatment status.
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Long-Term Effectiveness of Burosumab: Change From Baseline in Serum Phosporus Over Time
Timeframe: 10 years
Long-Term Effectiveness of Burosumab: Change From Baseline in Serum 1,25(OH)2D Over Time
Timeframe: 10 years
Long-Term Effectiveness of Burosumab: Change From Baseline in Serum Alkaline Phosphatase (ALP) Over Time
Timeframe: 10 years
Long-Term Effectiveness of Burosumab: Change From Baseline in Serum FGF23 Over Time in Participants Not Undergoing Treatment With Burosumab
Timeframe: 10 years
Long-Term Safety of Burosumab: Change From Baseline in Phosphaturic Mesenchymal Tumor (PMT) Size Over Time as Assessed by Tumor Imaging
Timeframe: 10 years
Long-Term Safety of Burosumab: Number of Participants With New PMT Development as Assessed by Tumor Imaging
Timeframe: 10 years
Long-Term Safety of Burosumab: Change From Baseline in Serum iPTH Over Time
Timeframe: 10 years
Long-Term Safety of Burosumab: Change From Baseline in Serum Calcium Over Time
Timeframe: 10 years
Long-Term Safety of Burosumab: Change From Baseline in Urine Calcium Over Time
Timeframe: 10 years
Long-Term Safety of Burosumab: Change From Baseline Urinary Calcium/Creatinine Ratio
Timeframe: 10 years
Long-Term Safety of Burosumab: Change From Baseline in Serum Creatinine Over Time
Timeframe: 10 years
Long-Term Safety of Burosumab: Change From Baseline in Urine Creatinine Over Time
Timeframe: 10 years
Long-Term Safety of Burosumab: Change From Baseline in Urine Protein/Creatinine Ratio Over Time
Timeframe: 10 years
Long-Term Safety of Burosumab: Number of Participants With Nephrocalcinosis Over Time
Timeframe: 10 years
Long-Term Safety of Burosumab: Number of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs) and Related AEs
Timeframe: 10 years
Long-Term Safety of Burosumab: Number of Participants With Incidence and/or Progression of Spinal Stenosis Over Time
Timeframe: 10 years
Long-Term Safety of Burosumab: Number of Participants With Normal and/or Potentially Clinically Significant Pregnancy Outcomes
Timeframe: 10 years
Long-Term Effectiveness of Burosumab: Change From Baseline in Brief Fatigue Inventory (BFI) Scores in Adult Participants Over Time
Timeframe: 10 years
Long-Term Effectiveness of Burosumab: Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Scores in Pediatric Participants Over Time
Timeframe: 10 years
Long-Term Effectiveness of Burosumab: Change From Baseline in Brief Pain Inventory (BPI) Scores in Adult Participants Over Time
Timeframe: 10 years
Long-Term Effectiveness of Burosumab: Change From Baseline in PROMIS Pain Scores in Pediatric Participants Over Time
Timeframe: 10 years
Long-Term Effectiveness of Burosumab: Change From Baseline in PROMIS Physical Function Scores Over Time
Timeframe: 10 years
Long-Term Effectiveness of Burosumab: Change From Baseline in Short Form-36 version 2 (SF-36v2) in Adult Participants Over Time
Timeframe: 10 years
Long-Term Effectiveness of Burosumab: Change in Short Form-10 (SF-10) for Pediatric Participants Over Time
Timeframe: 10 years
Long-Term Effectiveness of Burosumab: Number of Participants With Changes From Baseline in Clinical Findings
Timeframe: 10 years
Long-Term Effectiveness of Burosumab: Number of Participants With Changes From Baseline in Resource/Health Utilization
Timeframe: 10 years